AnaptysBio, Inc. ANAB Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $25.56M-76.4% | $108.25M+41.8% | $76.32M+243% | $22.26M-19.8% | $27.77M-35.6% | ||
| $33.99M+33.0% | $25.56M-18.6% | $31.41M-17.0% | $37.82M-8.1% | $41.18M-3.3% | ||
| $26.2M+66.0% | $15.79M+54.7% | $10.21M-3.8% | $10.61M-24.9% | $14.13M+38.6% | ||
| $60.19M+45.6% | $41.35M-0.6% | $41.62M-14.1% | $48.43M-12.4% | $55.31M+4.8% | ||
| -$34.64M-152% | $66.9M+92.8% | $34.7M+233% | -$26.17M+5.0% | -$27.54M-185% | ||
| -135.5%-197pp | 61.8%+16.3pp | 45.5%+163pp | -117.5%-18.4pp | -99.2%-76.7pp | ||
| -$18.21M-5.8% | -$17.21M+12.2% | -$19.59M-57.7% | -$12.42M-5.7% | -$11.75M+3.1% | ||
| -$52.84M— | —— | $15.11M+139% | -$38.59M+1.8% | -$39.29M-80.3% | ||
| $40K-50.6% | $81K— | $0-100% | $39K-11.4% | $44K— | ||
| -$52.88M— | —— | $15.11M+139% | -$38.63M+1.8% | -$39.33M-80.5% | ||
| -206.9%— | —— | 19.8%+193pp | -173.5%-31.9pp | -141.6%-91.1pp | ||
| -$1.84— | —— | $0.52+139% | -$1.34-4.7% | -$1.28-93.9% | ||
| -$34.51M-151% | $67.03M+92.4% | $34.84M+234% | -$26.03M+5.0% | -$27.39M-188% | ||
| -135%-197pp | 61.9%+16.3pp | 45.7%+163pp | -116.9%-18.3pp | -98.6%-76.5pp | ||
| -$34.64M-152% | $66.9M+92.8% | $34.7M+233% | -$26.17M+5.0% | -$27.54M-185% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is AnaptysBio, Inc.'s revenue?
- AnaptysBio, Inc. (ANAB) generated $232.4M in revenue over the trailing twelve months, up 107.7% year over year.
- Is AnaptysBio, Inc. profitable?
- AnaptysBio, Inc. is not currently profitable: it reported a net loss of $115.7M over the trailing twelve months, a -49.9% net margin.
- What is AnaptysBio, Inc.'s earnings per share?
- AnaptysBio, Inc.'s diluted EPS over the trailing twelve months is $-3.94.
- Where does AnaptysBio, Inc.'s income statement data come from?
- Every line is extracted from AnaptysBio, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
